I like your third think - informative, the other two seem to be...

I like your third think - informative, the other two seem to be something CYP likely paid for wouldn't you think?

Re your last paragraph - CYP is going to require patience of course, but its a bargain down here relative to its trials and standing in the stem-cell sector.

Clearly, it could be a bargain down here in some possible future scenarios (for instance a takeover offer at multiples of current price from a returning bidder), but absent takeover offers quite a lot of patience is going to be required before news comes out.

In your opinion do you think CYP will wait to see what MSB and then the FDA do with their BLA resubmission regarding GvHD or do you think they will go ahead irrespective of any news?

Also have you tried to explore how many clinics there are in the US that would potentially have a stream of patients with GvHD as a result of them typically treating various types of cancers etc?

I started to do that exercise - it didn't seem to me to be all that difficult because the cancer treatment centres tended to be in clusters and to make their presence known to people who migt want to use their services.

But I didn't actually complete the exercise.